



Axxam Enters CNS Partnership with Lundbeck for Lead Identification

Milan, Italy - December 6, 2023 - Axxam S.p.A. announces the formalization of a partnership with Lundbeck A/S, aimed at supporting Lundbeck for early-stage drug discovery programs related to CNS indications.

The signature of this first partnership agreement between Axxam and Lundbeck, for the identification and qualification of small molecules relevant to CNS targets, comes after more than five years of successful collaboration in assay development and High-Throughput Screening. The partnership relies on Axxam's science-driven approach to deliver qualified hits and leads, also for complex targets, through an optimized and elaborated screening funnel involving a panel of experts in the fields, including but not limited to automation, cell biology, electrophysiology, HTS, imaging, and compound profiling. Furthermore, within this partnership, Lundbeck will also have access to Axxam's prestigious compound collection AXxDiversity composed of over 345.000 carefully selected compounds.

Dr. Stefan Lohmer, Co-founder & Chief Executive Officer of Axxam, commented "We are thrilled and feel privileged to support Lundbeck through this partnership in the mission to discover and develop novel drugs for the treatment of neurological diseases."

Dr. Tarek Samad, SVP & Global Head of Research, Corporate Patents & Trademarks, Lundbeck added: "We are excited to partner with Axxam and leverage a rich compound collection and state of the art screening abilities. We look forward to a productive partnership aimed at discovering and delivering novel chemical entities to expand Lundbeck's discovery pipeline and bring therapies for patients with unmet needs."

About Axxam S.p.A.

Axxam is an innovative Partner Research Organization (iPRO) providing integrated discovery services across the life sciences industries with headquarters located in Bresso (Milan, Italy). Within the drug discovery disciplines, Axxam supports pharma and biotech companies, start-ups, patient foundations as well as academic groups in their journey from target assessment and hit identification to lead generation, over all therapeutic areas and target classes. Axxam's services include assay development, high-throughput screening, hit qualification and hit-to-lead. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information, please visit www.axxam.com.

About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research.

We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.